Good News

After Conmed Biosciences, an enterprise in the park, was listed on HKEx in July

another enterprise in the park

completed Round A financing of RMB 25 million

       Recently, Chengdu ExAb Biotechnology Co., Ltd. (hereinafter referred to as EXAB) completed the Round A financing of RMB 25 million.

       EXAB is a biomedical high-tech company founded in Chengdu Chengdu High-tech Zone by a returnee entrepreneurial team led by immunization expert Professor Zhang Zhixin. The purpose of the establishment of EXAB is to continuously create international leading disease diagnosis and treatment technology for the benefit of mankind.

       Our immune system is always the first one to detect invading viruses, bacteria and tumors in our body. Through years of efforts, EXAB has established a series of analytical systems that use immune big data and AI to judge various diseases for the first time in the world.

       At present, a total of 32 kinds of diseases can be accurately judged by analyzing the immune data in 1ml of peripheral blood, including 15 common solid tumors, 5 hematologic tumors, and a variety of neurodegenerative diseases and autoimmune diseases that cannot be found by early diagnosis at present, such as Alzheimer's disease, Parkinson's disease, epilepsy and IgA nephropathy. EXAB has obtained 3 national invention patents, and another 10 invention patents are under formal examination.

       The AI disease analytical system based on immune big data established by EXAB can be used not only for early screening and diagnosis of various diseases, but also for evaluating the therapeutic effect and developing new individualized treatment regimens.

       The current round of financing of EXAB will be used to expand its production base in Chengdu, start a series of applications for certificates of early tumor screening medical equipment and clinical trials, and develop new tumor targeted therapy technologies.

Source: WeChat Official Account of EXAB